Head, Cyclotron Radiochemistry Unit
Hadassah-Hebrew University Hospital
Jerusalem, Israel.
Tel : W-02 6777931
Fax : 02 6421203
email : eyalmi@ekmd.huji.ac.il
1987 – 1990: Tel-Aviv University, Chemistry, B. Sc. (cum laude)
1991 – 1994: Tel-Aviv University, Org. Chem. Direct Course to Ph. D. Prof. Rozen S. Studies (cum laude)
1994 – 1996: Washington University Medical School, Org. & Radio Chem. Post Doctoral Fellow: Prof. Welch MJ
1996 – 2002: Hebrew University, Nuclear Medicine. Lecturer
2003 – 2006: Hebrew University, Nuclear Medicine. Senior Lecturer
Current positions
2007: Hebrew University, Nuclear Medicine. Associate Professor
1996 October: Hadassah Hospital, Medical Imaging. In charge of the Cyclotron Radiochemistry Facility
Editorial & Scientific Committees
2008: International Associate Editor of Molecular Imaging & Biology.
2006: Member of the Scientific Committee, World Congress of Nuclear Medicine and Biology (WCNMB). Seoul, Korea.
2005: Editorial board member of Nuclear Medicine & Biology, Official Journal of the Society of Radiopharmaceutical Sciences.
Awards
1994: Fulbright Researcher Award
1994: The World Zionist Organization Award
1993: Young Researcher-Wolf
Foundation Award
1993: David and Paulina Trotski Award
1993: Chemist’s Organization Scholarship
1992: Chemist’s Organization Scholarship
1991: Chemist’s Organization Scholarship
1991: Dean’s Excellence Award
1990: Dean’s Excellence Award
Grants
G8. 2007: Israel Science Foundation (ISF), Targeting the Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) in cancer - Development of PET molecular imaging agents. Eyal Mishani PI. (181,000 NIS, 3 Years, 100%)
G7. 2005: Joint German-Israeli Research Program, Development and clinical application of a PET-SERT ligand labeled with fluorine-18. Eyal Mishani PI, Roland Chisin co-PI. (85,000 Eu, 3 Years, 100%).
G6. 2003: NIH, Functional dopamine neurons from human ES cells. Reubinoff Benjamin Eitan PI, Ben Hur Tamir Co-Investigator, Bergman Hagi Co-Investigator, Mishani Eyal Co-Investigator, Segal Menahem Co-Investigator. ($237,000/year for 4 years, 10%)
G5. 2001: A start-up company was established for research on EGFR, Hadassah-Hebrew University -Naiot. (Collaboration with Prof. A. Levitzki)
G4. 2001: Israel cancer Association, Evaluation of prostate cancer with PET using [C-11]choline. M. Bocher, E. Mishani, R. Chisin. ($10,000, 100%) # 23, 26; # abstracts 13.
G3. 1999: Binational Science Foundation, Labeled PET tracers for EGFr-TK and estrogen receptors. E. Mishani PI, Collaboration with Prof. A. Levitzki. ($114,000, 3 Years, 100%) # 17, 20, 21, 22, 25, 27, 28. # abstracts 9, 10.
G2. 1999: International Atomic Energy Agency Grant, National and regional production of fluorinated radiopharmaceuticals – clinical and scientific aspects. R. Chisin, E. Mishani. ($150,000, 3 Years, 100%) # 16, 19, 30. # abstracts 5, 6, 7, 8, 12.
G1. 1999: Magnet with Teva, A new MAO-B inhibitor-anti Parkinson drug; Use of PET for in-vivo measurement of Human Monoamine Oxidase B. E. Mishani, R. Chisin. ($90,000, 3 Years, 100%). # 34
Organized Seminars
1. A.Clinical use of 18FDOPA & 11C Choline, Prof. Fanti, University of Bologna.
B. Erbitux and other TK inhibitors in targeted therapy of Colon Carcinoma, Dr. Pantaleo, Policlinico S. Orsola-Malpighi Hospital. Hadassah Hebrew University Hospital, April 2006.
2. Micro-PET, Prof. M. J. Welch, Washintgton University. Hadassah Hebrew University Hospital, November 2004.
3. A. The development of receptor radioligands for brain, heart and lung.
B. Protein synthesis in tumor tissue quantified by PET.
C. Molecular biology and PET.
Prof. W. Vaalburg, Groningen university hospital. Hadassah Hebrew University hospital, August 1999.
4. Targetry and in target chemistry, Nuclear Research Center Negev, and prof. F. Helus. Hadassah Hebrew University hospital, May 1998.
5. PET Radiopharmaceuticals, Prof. M. J. Welch, Washintgton University. Hadassah Hebrew University Hospital, November 1997.
Publications
Papers in Peer-Review Journals, Original Research papers.
1. S. Rozen, E. Mishani and M. Kol (1991). A Novel Electrophilic Methoxylation (With a little Help From F2). J. Am. Chem. Soc. 114: 7643-7645.
2. E. Appelman, D. French, E. Mishani and S. Rozen (1993). Synthesis, Characterization, and Reaction Chemistry of tert-Butyl Hypofluorite. J. Am. Chem. Soc. 115: 1379-1382.
3. S. Rozen, E. Mishani (1993). Conversion of Esters to -Difluoro Ethers using BrF3. J. Chem. Soc. Chem. Commun. 1761-2.
4. S. Rozen, A. Bar Haim and E. Mishani (1994). A new Efficient Route to Nitro Acids. Oxidation of Amino Acids with HOF/CH3CN. J. Org. Chem. 59: 1208-9.
5. S. Rozen, E. Mishani, I. Ben-David and M. Kol (1994). The Chemistry of Methyl Hypofluorite with Various Unsaturated Centers. J. Org. Chem. 59: 4281-4284.
6. S. Rozen, E. Mishani, A. Bar-Haim (1994). A novel Carbonyl to CF2 Transformation Using BrF3. J. Org. Chem. 59: 2918.
7. S. Rozen, A. Bar-Haim and E. Mishani (1994). Fluorination of Nitro Compounds with Acetyl Hypofluorite. J. Org. Chem. 59: 6717.
8. S. Rozen, E. Mishani (1994). A novel Method for Converting Aromatic Acids into Trifluoromethyl Derivatives Using BrF3. J. Chem. Soc. Chem. Commun. 2081.
9. E. Mishani, C. S. Dence, T. J. McCarthy and M. J. Welch (1995). A Study of - Trifluoro Toluenes Mediated [18F] Fluoro - for - Nitro Exchange. A Useful Intermediate in the Synthesis of Highly Fluorinated Radiopharmaceuticals. J. Labl. Comp. Radiopharm., 37: S575-7.
10. C. S. Dence, E. Mishani, T. J. McCarthy, M. J. Welch (1995). Evaluation of a Microwave Cavity for the Synthesis of PET Radiopharmaceuticals. J. Labl. Comp. Radiopharm. 37: S115-6.
11. S. Rozen, Y. Bareket, I. Ben-David and E. Mishani (1995). The Impact of F2 on Organic Chemistry. J. Labl. Comp. Radiopharm. 37: S641-3.
12. E. Mishani, C. S. Dence, T. J. McCarthy and M. J. Welch (1996). Formation of Phenylpiperazines by a Novel Alumina Supported Bis-Alkylation. Tet. Lett., 37: 319-322.
13. E. Mishani, R. M. Brodbeck, J. E. Krause, C. S. Dence, T. J. McCarthy and M. J. Welch (1997). Synthesis and Evaluation of A Fluorine-18 Labeled NK-1 Antagonist. J. Label. Compound. Radiopharm. 40: S653–655.
14. E. Mishani, Michael E. Cristel, Carmen S. Dence, Timothy J. McCarthy, Michael J. Welch (1997). Application of a Novel Phenylpiperazine Formation Reaction to the Radiosynthesis of 18FTFMPP, a Potent Serotonin Agonist. J. of Nucl. Med. and Biol. 24: 269-273.
15. I. Ben-David, E. Mishani, S. Rozen (1998). tert-Butyl Hypofluorite - An Electrophilic tert-Butoxylation Agent. J. Org. Chem. 63: 4632.
16. E. Mishani, N. Lifshits, A. Osavistky, J. Kaufman, N. Ankry, N. Tal, R. Chisin (1999) Radiation Levels in Cyclotron-Radiochemistry Facility measured by A Novel Comprehensive Computerized Monitoring System. Nucl. Instr. Meth. phys. res. A, 425: 332-342.
17. E. Mishani, T. A. Bonasera, Y. Rozen, G. Ortu, A. Gazit, A. Levitzki (1999). Fluorinated EGFR-TK inhibitor-based tracers for PET. J. Labl. Comp. Radiopharm., 42: S27-29.
18. I. Ben David, D. Rechavi, E. Mishani, S. Rozen (1999). A Novel synthesis of trifluoromethyl ethers via xanthates, utilizing BrF3. J. of Fluorine Chemistry, 97: 75-78.
19. Klein, M, Freedman, N, Mishani, E, Gimon, Z, Lotem, M, Chisin, R. (2000). PET and lymphoscintigraphic evaluation of malignant melanomas. Nuklear Medizin, 39:56-61.
20. M. Bocher, E. Mishani (2000). The Contribution of Positron Emission Tomography-PET to patient management in oncology. J. of the Israel Medical Association. 139, 64-67.
21. T. A. Bonasera, G. Ortu, Y. Rozen, Roman Krais, Nanette M.T. Freedman, Roland Chisin, A. Gazit, A. Levitzki and E. Mishani (2001). Potential 18F-Labeled Biomarkers for Epidermal Growth Factor Receptor Tyrosine Kinase. J. of Nucl. Med. and Biol, 28: 359-37.
22. E. Mishani, I. Ben David, Y. Rozen, G. Ortu, A. Levitzki (2001). Carbon-11 Labeled Irreversible Inhibitors for Mapping Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK). J. Labl. Comp. Radiopharm. 44: S94-96.
23. E. Mishani, I. Ben David (2001). [C-11] Acryloyl Chloride- A Fully Automated Preparation and Reaction with Model Amine. J. Labl. Comp. Radiopharm. 44: S475-476.
24. E. Mishani, I. Ben-David, Y. Rozen, D. Laki, M. Bocher, R. Chisin, (2001). [C-11]Choline - Automated Preparation and Clinical Utilization. J. Labl. Comp. Radiopharm. 44: S379-381.
25. M. Bocher, R. Chisin, Y. Parag, N. Freedman, Y. Meir, H. Lester, E. Mishani, O. Bone (2001). Cerebral Activation Associated with Sexual Arousal in Response to A Pronographic Clip: A [O-15]Water PET Study in Heterosexual Men. Neuroimage, 14: 105-117.
26. G. Ortu, I. Ben-David, Y. Rozen, A. Levitzki, E. Mishani (2001). Biological Evaluation of A Novel C-11 Labelled Irreversible EGFRTK Inhibitor. The Quar. J. of Nucl. Med. 45: S7.
27. E. Mishani, I. Ben-David, Y. Rozen (2002). Improved method for the quality assurance of [C-11]choline. J. of Nucl. Med. and Biol. 29: 359-362.
28. G. Ortu, I. Ben-David, Y. Rozen, N. M. Freedman, R. Chisin, A. Levitzki, E. Mishani (2002). In-vitro and In-vivo investigation of an irreversible labeled EGFR inhibitor (ML03) and its potential as PET biomarker in Cancer and feasibility as an anticancer drug. Int. J. of Cancer, 101: 360-37.
29. I. Ben-David, Y. Rozen, G. Ortu and E. Mishani (2003). Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [C-11]Acryloyl chloride. Appl. Rad. Isotp. 58: 209-217.
30. Einat Even-Sapir, Ur Metser, Gideon Flusser, Limor Zuriel, Yehuda Kollender, Hedva Lerman, Gennady Lievshitz, Ilan Ron, and Eyal Mishani (2004). Assessment of malignant skeletal disease: Initial experience with 18F-Fluoride PET/CT and comparison between 18F-Fluoride PET and 18F-Fluoride PET/CT. J. Nuc. Med. 45: 272-278.
31. Mishani, G. Abourbeh, Y. Rozen, O. Jacobson, D. Laky, I. Ben David, A. Levitzki, M. Shaul (2004). Novel Carbon-11 Labeled 4-Dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET Bioprobes for Molecular Imaging of EGFR-positive Tumors. J. of Nucl. Med. and Biol. 31: 469-476.
32. M. Shaul, G. Abourbeh, O. Jacobson, Y. Rozen, D. Laky, A. Levitzki and E. Mishani (2004). Novel Iodine-124 Labeled EGFR Inhibitors as Potential PET Agents for Molecular Imaging in Cancer. Bioorg. Med. Chem. 12: 3421-3429.
33. Y. Barda, N. Cohen, V. Lev, N. Ben-Aroya, Y. Koch, E. Mishani, M. Fridkin, C. Gilon (2004). Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. J. of Nucl. Med. and Biol. 31: 921-933.
34. Orit Jacobson, Yossi Bechor, Avi Icar, Nurit Novak, Atalia Birman, Hanit Marom, Ludmila Fadeeva, Elizabeth Golan, Ilan Leibovitch, Mordechai Gutman, Einat Even-Sapir, Roland Chisin, Michael Gozin and Eyal Mishani (2005). Prostate Cancer PET Bioprobes: Synthesis of [18F]-Radiolabeled Hydroxyflutamide Derivatives. Bioorg. Med. Chem. 13: 6195-6205.
35. Nanette MT Freedman, Eyal Mishani, Yodphat Krausz, Jolie Weininger, Hava Lester, Eran Blaugrund, Daphna Ehrlich, Roland Chisin (2005). In-Vivo Measurement of Brain Monoamine Oxidase B (MAO-B) Occupancy by Rasagiline, using 11C-L-Deprenyl and Positron Emission Tomography (PET). J. Nuc. Med. 46: 1618-1624.
36. Mishani E, Abourbeh G, Jacobson O, Shaul M, Ben-Daniel R, Dissoki S, Rozen Y, Levitzki A. (2005). High affinity EGFR irreversible inhibitors with diminished chemical reactivities as PET- imaging agent candidates of EGFR over-expressing tumors. J. Med. Chem. 48: 5337-5348.
37. Ofer N. Gofrit, Eyal Mishani, Marina Orevi, Martine Klein, Nanette Freedman, Dov Pode, Amos Shapiro, Ran Katz, Eugene Libson, Roland Chisin (2006). Contribution of 11C-Choline PET/CT to preoperative Staging of Patients with Advanced Transitional Cell Carcinoma. J. of Urology. 17:940-944.
38. Einat Even-Sapir, Ur Metser, Eyal Mishani, Gennady Lievshitz, Hedva Lerman, Ilan Leibovitch (2006). The detection of bone metastases by 99mTC-MDP planar bone scintigraphy, single and multi-field-of-views SPECT, 18F-fluoride PET and 18F-fluoride PET -CT. Prospective study in 44 patients with high risk prostate cancer. J. Nuc. Med. 47: 287-297.
39. Ori Wald, Ido D. Weiss, Hanna Wald, Hadas Shoham, Yochay Bar-Shavit, Katia Beyder, Eithan Galun, Lola Weiss, Liat Flaishon, Idit Shachar, Arnon Nagler, Bao Lu, Craig Gerard, Ji-Liang Gao, Eyal Mishani, Joshua Farber, and Amnon Peled (2006). IFN- acts on T cells to induce NK cell mobilization and accumulation in target organs. Journal of Immunology. 176(8):4716-29.
41. A. Levitzki and E. Mishani (2006). Tyrphostin and other Tyrosine kinase inhibitors. Annual Review Biochemistry, 75: 93-10.
42. Orit Jacobson, Desideriu Laky, Kathryn E. Carlson, Sharona Elgavish, Michael Gozin, Einat Even-Sapir, Ilan Leibovitc, Mordechai Gutman, Roland Chisin, John A. Katzenellenbogen and Eyal Mishani (2006). Chiral dimethylamine flutamide derivatives - modeling, synthesis, androgen receptor affinities, and carbon-11 labeling. J. of Nucl. Med. and Biol. 33 :695-704.
43. Asher Shushan, Hannah Ben-Bassat, Eyal Mishani , Neri Laufer, BenjamineY. Klein, and Nathan Rojansky (2007). Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertility and Sterility. 87 (1): 127-135.
44. Galith Abourbeh, Samar Dissoki, Orit Jacobson, Amir Litchi, Revital Ben Daniel, Desirediu Laki, Alexander Levitzki and Eyal Mishani (2007). Evaluation of radiolabeled ML04, a putative irreversible inhibitor of the Epidermal Growth Factor receptor, as bioprobe for PET imaging of EGFR overexpressing tumors. J. of Nucl. Med. and Biol. 34, 55-70.
46. E. Mishani, G. Abourbeh (2007). Cancer Molecular Imaging: Radionuclide-Based biomarkers of the Epidermal Growth Factor Receptor (EGFR). Current Topics in Medicinal Chemistry. 7 (18): 1755-72.
47. Einat Even-Sapir, Eyal Mishani, Gideon Flusser, Ur Metser (2007). 18F-Fluoride Positron Emission Tomography and Positron Emission Tomography/Computed Tomography. Seminars in Nuclear Medicine. 37 (6), 462-469.
48. Orit Jacobson, Eyal Mishani (2008). [11C]-Dimethylamine as a labeling agent for PET biomarkers. Appl. Rad. Isotp. 66, 188-193.
49. A Bar-Haim Erez , N Freedman , N Katz , O Abramsky , E Mishani, R Chisin (2008). Neural Mechanism Of Visual Attention In Unilateral Spatial Neglect Following Stroke: A Preliminary PET Study. Israel Journal of Occupational Therapy.17(1), E3-22.
50. Ilovich O, Jacobson O, Aviv Y, Litchi A, Chisin R, Mishani E. (2008). Formation of fluorine-18 labeled diaryl ureas-labeled VEGFR-2/PDGFR dual inhibitors as molecular imaging agents for angiogenesis. Bioorg Med Chem. 16, 4242-4251.
51. Ben Daniel R, Deuther-Conrad W, Scheunemann M, Steinbach J, Brust P, Mishani E. (2008). Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter. Bioorg Med Chem. 16, 6364-6370.
52. Eyal Mishani, Galith Abourbeh, Martin Eiblmaier and Carolyn J. Anderson (2008). Imaging of the EGFR and EGFR tyrosine kinase overexpression in tumors. Current Pharmaceutical Design,14 (28): 2983-2998.
53. Samar Dissoki, Renana Eshet, Hana Billauer, Eyal Mishani (2009). Modified PEG-anilinoquinazoline derivatives as potential EGFR PET agents. J. Labl. Comp. Radiopharm. 52, 41-52.
54. Ohad Ilovich, Ola Åberg, Bengt Långström and Eyal Mishani. (2009). Rhodium-mediated [11C]Carbonylation: A Library of N-Phenyl-N’-{4-(4-quinolyloxy)-phenyl}-[11C]-urea Derivatives as Potential PET Angiogenic Probes. J. Labl. Comp. Radiopharm. 52, 151-157.
55. Ruvinsky I, Katz M, Dreazen A, Gielchinsky Y, Saada A, Freedman N, Mishani E, Zimmerman G, Kasir J, Meyuhas O. (2009). Mice Deficient in Ribosomal Protein S6 Phosphorylation Suffer from Muscle Weakness that Reflects a Growth Defect and Energy Deficit. PLoS ONE. 2009 May 19;4(5):e5618.
56. Eyal Mishani, Aviv Hagooly (2009). Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer. J. Nuc. Med. 50 (8):1199-1202.
57. E. Afergan, H. Epstein, N. Koroukhov, M. Klein, A. Litchi, E. Mishani, G. Golomb. (2009). Biodistribution and Imaging studies of 67Ga-Labeled Liposomes in Rabbits with a Vascular Injury. Journal of drug delivery science and technology. 19, 263-268.
58. O. Ilovich, H. Billauer, S. Dotan and E. Mishani. (2010). Labeled 3-aryl-4-indolylmaleimide derivatives and their potential as angiogenic PET biomarkers. Bioorg Med Chem. 18 (2), 612-620.
59. O. Cohen, E. Mishani, S. Rozen. (2010). From carboxylic acids to the trifluoromethyl group using BrF3. Tetrahedron 66, 3579–3582.
60. M.A. Pantaleo, E. Mishani, C. Nanni, L. Landuzzi, S. Boschi, G. Nicoletti, S. Dissoki, P. Paterini, P.P. Piccaluga, F. Lodi, P.L. Lollini, S. Fanti and G. Biasco. (2010). Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Molecular Imaging & Biology. DOI: 10.1007/s1 1307-010-0315-z.
61. O. Ilovich, H. Billauer, S. Dotan, N.M.T. Freedman, M. Bocher, and E. Mishani. (2010). Novel and simple carbon-11 labeled ammonium salts as PET agents for myocardial perfusion imaging. Molecular Imaging and Biology. 10.1007/s1 1307-010-0336-7.
62. Y. Krausz, N. Freedman, R. Rubinstein, E. Lavie, M. Orevi, S. Tshori, A. Salmon, B. Glaser, R. Chisin, E. Mishani, D.J. Gross. (2010). 68Ga-DOTA-NOC PET/CT imaging of Neuroendocrine Tumors: Comparison with 111In-DTPA-Octreotide (OctreoScan®). Molecular Imaging & Biology. 10.1007/s1 1307-010-0374-1.
Patents
1. E. Mishani, T. A. Bonasera, Y. Rozen, G. Ortu, A. Gazit, A. Levitzki. Novel Epidermal Growth Factor Receptor-Kinase Binding Compounds for Positron Emission Tomography. U.S. Patent No. 6,126,917 (2000).
2. E. Mishani, I. Ben David, Y. Rozen, G. Ortu, A. Levitzki, Radiolabeled inhibitors for Epidermal Growth Factor Receptor Tyrosine Kinase and their use in radioimaging and radiotherapy. U.S. Patent No. 6,562,319 (2003).
3. E. Mishani, Y. Rozen, G. Abourbeh, A. Levitzki. Novel EGFR-TK irreversible inhibitors for cancer therapy, radiotherapy and diagnosis. U.S. Patent No. 7,172,749(2007).
Applied to U.S. patent (2006).
5. Eyal Mishani, Orit Jacobson. 11C and 18F- labeled Androgen-Receptor (AR) ligands for use in the treatment and diagnosis of AR-related pathologies.
Applied to U.S. patent (2006).
Invited Lectures
1. PET molecular Imaging agents – Labeled Magic bullets. Rambam Hospital, Haifa, Israel, 2010.
2. Novel PET tracers for imaging of cancer patients. Annual Conference of the European Organization for Research and Treatment of Cancer, Radiation Oncology Group (EORTC-ROG), Haifa, Israel, 2009.
3. PET radiopharmaceuticals production and clinical application. Soreq Nuclear research center, Israel, 2008.
4. Development of Radiolabeled Inhibitors of EGFR and VEGFR Tyrosine Kinases as PET agents. "Molecular imaging for better diagnosis and management of diseases" Bayer Healthcare, Bayer Schering pharma, Life Sciences Workshop Series, Berlin, Germany, 2008.
5. PET isotopes and radiopharmaceuticals: production and clinical application. Symposium honoring the 90th birthday of Prof. Israel Dostrovsky; Outward Bound: From nuclear chemistry to Solar Neutrinos. Weizmann Institute of Science, Israel 2008.
6. PET imaging bioprobes in oncology: design, labeling and preclinical studies. Department of Biological Regulation, Weizmann Institute of Science, Israel 2007.
7. PET bioprobes for molecular imaging. Hybrid imaging (PET/CT) symposium, Philips. Israel 2007.
8. Personalized Medicine: Image guided treatment. Israel Medical Convention, Jerusalem, Israel 2007.
9. Receptor based Molecular imaging in Oncology. New Trends in Molecular Imaging and Nuclear Medicine. Annual Conference at the University of Bologna Italy. 2006
10. Visualizing EGFR in cancer. Azienda Ospedaliera S.Orsola-Malpighi University Hospital. Bologna, Italy. 2005
11. Animal-PET and Micro-PET molecular imaging. Imaging in laboratory animals- Experimental approaches and techniques. Hebrew University/Hadassah Hospital. The Authority for Animal Facilities, Israel, 2005.
12. PET Molecular Imaging of Angiogenesis and Gene Therapy. Rambam Hospital & Rapaport Institute, Haifa, Israel, 2004.
13. Labeled Molecular Imaging Agents of the EGFR-TK for Specific In-vivo Diagnostic and, Image Guided Treatment of Cancer. Bioorganic Chemistry. The 69th Meeting of the Israel Chemical Society, Tel Aviv, Israel, 2004.
14. PET Radiopharmaceuticals for Oncology. Rambam Hospital & Rapaport Institute, Haifa, Israel, 2004.
15. Direct labeling of Tyrosine Kinase ligands. Work-shop; Modern Imaging Technology, Annual Conference of the Society of Nuclear Medicine, New Orleans, USA, 2003. Invited lecture.
16. The Inter-phase, Nuclear physics-Nuclear medicine. Mini-seminar, The Israeli pharmacist Organization, Health Ministry. Sorasky Medical Center, Tel Aviv, 2003.
17. PET-Oncology, [C-11]Choline and EGFR labeled inhibitors, Tel Aviv University, School of Chemistry, 2001.
18. Positron Emission Tomography - Overview, Nuclear Research Center – Negev, Israel, 1998.
19. Positron Emission Tomography - Overview, Nuclear Research Center – Sorek, Israel, 1998.
20. Alkylhypofluorite and Electrophilic Fluorination, Corporate Science and Technology Center, Air Products and Chemicals, USA, 1996.
Abstracts of Papers Presented In Scientific Meetings (Peer Review)
1. S. Rozen, E. Mishani, Y. Bareket and A. Bar-Haim. F2 as a General Reagent in Organic Chemistry. The 59th meeting of the Israel Chemical Society (1994). Beer Sheva, Israel.
2. S. Rozen, E. Mishani, Y. Bareket and A. Bar-Haim. F2 as a General Reagent in Organic Chemistry. International Conference on Fluorine Chemistry (1994). Kyoto, Japan.
3. S. Rozen, E. Mishani, Y. Bareket and A. Bar-Haim. Introducing BrF3 and some Novel Hypofluorites to Organic Chemistry. 14th International Symposium on Fluorine Chemistry (1994). Yokohama Japan.
4. E. Mishani, M. E. Cristel, T. J. McCarthy, M. J. Welch. Radiosynthesis Binding Affinity and Biodistribution of 3-[F-18]fluoro-N-(-trifluoro-m-tolyl)piperazine (FTFMPP), a Radioligand for the Serotonin System. The 43rd Annual Meeting of the Society of Nuclear Medicine (1996). Denver, Colorado (J. Nucl. Med., 37, 40p).
5. E. Mishani, E. Loewenthal, N. Tal, M. Arad, Y. Kaufman, A Osovizky. Safety Control And Radiation Monitoring System for Cyclotron Sites. The second Regional Mediterranean Congress on Radiation Protection (1997). Tel-Aviv, Israel.
6. M. Ghyoot, F. Schmitz, R. Verbruggen, P. E. Boeyen, E. Mishani, G. Bormans. Improvment in Fluoride Production in IBA targrt. Proceedings of the Seventh Workshop on Targetry and Target Chemistry (1997). Heidelberg, Germany.
7. E. Mishani, A. Osavistky, N. Tal, R. Chisin. Radiation Levels in Cyclotron Radiochemistry Facility. 10th Annual International PET Conference (1998).Boston, USA.
8. R. Chisin, M. Klein, N. Freedman, E. Mishani, E. Shiloni, Z. Gimon, M. Lotem. PET and Lymphoscintigraphic Evaluation of Malignant Melanomas: The Hadassah Hospital Experience. 10th Annual International PET Conference (1998). Boston, USA.
9. E. Mishani, T. A. Bonasera, Y. Rozen, G. Ortu, A. Gazit, A. Levitzki, Potential PET Biomarkers for Epidermal Growth Factor Receptor Tyrosine Kinase. 2000 International chemical congress of pacific basin societies, (2000). Honolulu, Hawaii.
10. G. Ortu, I. Ben-David, Y. Rozen, A. Levitzki, E. Mishani. Biological Evaluation of A Novel C-11 Labelled Irreversible EGFRTK Inhibitor. 12th International Symposium on Radiopharmacology, (2001). Interlaken
11. M. Bocher, O. Bone, Y. Parag, N. Freedman, Y. Meir, H. Lester, E. Mishani, R. Chisin. Cerebral Activation Associated with Sexual Arousal in Response to A Pronographic Clip: A [O-15]Water PET Study in Heterosexual Men. The 48 Annual Meeting of the Society of Nuclear Medicine (2001). Toronto, Canada.
12. E. Mishani, D. Laky, D. Wajnblum, R. Chisin. PET Radipharmaceuticals Dispending Unit. The 49th Annual Meeting of the Society of Nuclear Medicine (2002). Los Angeles, USA.
13. R. Chisin, N. Freedman, R. Rubinstein, E. Mishani, M. Bocher, H. Lester, Y. Shoshan, J. M. Gomori, T. Siegal. Can C-11 Choline PET contribute to the differentiation of recurrent high-grade brain tumor from post-radiation necrosis? The 49th Annual Meeting of the Society of Nuclear Medicine (2002). Los Angeles, USA.
14. E. Mishani, A. Levitzki, G. Abourbeh, G. Ortu, I. Ben-David, Y. Rozen, H. Lester, N. Fridman, R. Chisin. Novel Irreversible [C-11]EGFR-TK Inhibitors for Cancer Imaging Diagnosis. The 50 annual Conference of the Society of Nuclear Medicine (2003), New Orleans, USA.
15. E. Mishani, G. Abourbeh, G. Ortu, Y. Rozen, I. Ben David, S. Froimovici, S. Dissoki, A. Gazit, A. Levitzki. Novel EGFR Irreversible Tyrosine Kinase Inhibitors for the Diagnostic and Therapeutic Treatment of Cancer. The 15th International Symposium on Radiopharmaceutical Chemistry (2003), Sydney, Australia.
16. E. Mishani, G. Abourbeh, Y. Rozen, D. Laki, A. Levitzki. Carbon-11 labeling of 4-Dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazolin-6-yl]-amides, a new class of EGFR irreversible inhibitors. The 15th International Symposium on Radiopharmaceutical Chemistry (2003), Sydney, Australia.
17. E. Mishani. PET Bioprobes for EGFR Molecular Imaging of Cancer. 21st International Acadmey of Tumor Marker Oncology Conference, (2004), Xi'an, China.
18. Y. Barda, N. Cohen, V. Lev, N. Ben-Aroya, Y. Koch, E. Mishani, M. Fridkin, C. Gilon. Metal backbone cyclization: ovel 99mTc labeled GNRH analog as potential SPECT molecular imaging agent in cancer. 3rd International and 28th European Peptide Symposium, (2004), Prague, Czech Republic.
19. Nanette Freedman, Eyal Mishani, Yodphat Krause, Eran Blaugrund, Daphna Ehrlich, Roland Chisin. In Vivo measurement of brain monoamine oxidase (MAO-B) activity after Resagiline treatment, using L-[11C]Deprenyl and Positron Emission Tomography (PET). 9th International Congress of Parkinson's Disease and movment Disorders (2005), New Orleans (USA).
20. Galith Abourbeh, Orit Jacobson, Mazal Shaul, Taly Ben Daniel, Alexander Levitzki and Eyal Mishani. High Affinity EGFR irreversible inhibitors with diminished chemical reactivities as candidates for PET-imaging biomarkers of EGFR over-expressing tumors. Federation of Israel Societies for Experimental Biology congress (2005), Eillat Israel.
21. Nasi Cohen, Yaniv Barda, Chaim Gilon, Eyal Mishani. Metal Backbone Cyclization: Blood Stability Evaluation of a Novel 99mTc- Labeled GnRH Analog as a Potential SPECT Molecular Imaging Agent in Cancer. The forth annual meeting of the society for molecular imaging (2005), Cologne, Germany.
22. Orit jacobson, Michael Gozin, Eyal Mishani. [18F]-Radiolabeled Hydroxyflutamide Derivatives as Prostate Cancer Imaging Agent Candidates. The forth annual meeting of the society for molecular imaging (2005), Cologne, Germany.
23. Samar Dissoki, Eyal Mishani. Radiosynthesis of [F-18]-Anilinoquinazoline-PEG Derivatives as EGFR Molecular Imaging Agents. The forth annual meeting of the society for molecular imaging (2005), Cologne, Germany.
24. Galith abourbeh, Orit Jacobson, Revital Ben Daniel, Alexander Levitzki, Eyal Mishani. Potent EGFR Irreversible Inhibitors with Enhanced Chemical & Biological Stabilities as PET-Imaging Agent Candidates of EGFR Over Expressing Tumors. The forth annual meeting of the society for molecular imaging (2005), Cologne, Germany.
25. Gofrit ON, Mishani E, Orevi M, Klein M, Freedman N, Pode D, Pode D, Shapiro A, Katz R, Libson E, Chisin R. Contribution of 11C-choline pet/ct to preoperative staging of patients with advanced transitional cell carcinoma. JOURNAL OF UROLOGY 175 (4): 316-316 981 Suppl. S APR 2006.
26. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases by 99mTc-MDP planar bone scintigraphy, single and multi-field-of-views SPECT, 18F-Fluoride PET and 18F-Fluoride PET-CT. Prospective study in 44 patients with high-risk prostate cancer. JOURNAL OF UROLOGY 175 (4): 501-501 1553 Suppl. S, APR 2006.
27. Abourbeh G., Dissoki S., Litchi M., Laki D., Levitzki A., Mishani E. Radiolabeled ML04, an irreversible inhibitor of the EGFR tyrosine kinase, a candidate bioprobe for PET-imaging of EGFR overexpressing tumors. The Annual Meeting of the Israel Society for Biochemistry and Molecular Biology (2006), Rehovot, Israel.
28. M. Orevi, O.N. Gofrit, N. Freedman, E. Mishani, M. Klein, M. Bocher, R. Marciano, Y. Krausz, R. Chisin. Pitfalls in interpretation of C-11 Choline PET and PET/CT in urinary tract and prostate cancer. The 53 annual Conference of the Society of Nuclear Medicine (2006), San Diego, USA.
29, Orit Jacobson, Kathryn E. Carlson, Einat Even-Sapir, John A. Katzenellenbogen Roland Chisin, and Eyal Mishani. Androgen Receptor novel radioligands: the impact of dimethylamine addition to the flutamide structure on metabolism.
9th congress of World Federation of Nuclear Medicine and Biology (2006), Seoul, Korea.
30. N. Freedman, E. Sprung, E. Mishani, R. Marciano, A. Litchi, I. Ruvinsky, O. Meyuhas, R. Chisin. FDG PET imaging using Discovery ST clinical PET/CT scanner to compare glucose metabolism in rpS6P-/- and wild-type mice. J Nucl Med. 2007; 48 (Supplement 2):267P.
31. Y Krausz, N Freedman, M Orevi, D Barak, E Mishani, B Glaser, R Rubinstein, M Klein, DJ Gross, R Chisin. F-DOPA-PET in Neuroendocrine Tumors: An Open Question? J Nucl Med. 2007; 48 (Supplement 2):127P.
32. Anat Shirvan, Hagit Grimberg, Galit Levin, Avi Cohen, Ayelet Reshef, Ayelet Axelrod-Balin, Aaron M. Allen, Eyal Fenig, Adam Steinmetz, David Groshar, Edna Inbar, Yulia Kundel, Eyal Mishani, and Ilan Ziv. Monitoring of Tumor Response to Therapy by 18F-ML-10, a Novel Small-molecule PET Tracer for Apoptosis: From Pre-clinical to Clinical Studies. The American Association for Cancer Research (AACR) (2008) Philadelphia.
33. Aaron M. Allen, Ilan Ziv, Eyal Fenig, Adam Steinmetz, David Groshar, Edna Inbar, Yulia Kundel, Eyal Mishani, Ayelet Reshef and Anat Shirvan. Phase 2 Study of 18F-ML-10, a novel PET Radiotracer of Apoptosis, in Early Detection of Response of Brain Metastases to Radiation Therapy. ASCO-NCI-EORTC Annual meeting on Molecular markers in Cancer (2008). USA
34. Ohad Ilovich, Ola Åberg, Bengt Långström and Eyal Mishani. Radiopharmaceutical Strategies for the imaging of Angiogenesis in Cancer. World Molecular Imaging Congress, Nice, France, 2008.
35. Samar Dissoki, Renana Eshet, Hana Billauer, Eyal Mishani. Modified PEG-anilinoquinazoline derivatives as potential EGFR PET agents. World Molecular Imaging Congress, Nice, France, 2008.
36. Anat Shirvan; Ayelet Reshef; Aaron Allen; Eyal Fenig; Adam Steinmetz; David Groshar; Eyal Mishani; Ilan Ziv. Apoptosis Imaging with PET-18F-ML-10 for early assessment of response of brain metastases to radiotherapy. The 56 annual Conference of the Society of Nuclear Medicine (2009), Toronto, Canada.
37. Funke, U. Fischer, S. Hiller, A. Ruehl, T. Mishani, E., Scheunemann, M. Deuther-Conrad, W. Brust, P. Steinbach, J. Radiosynthesis and in vitro evaluation of F-18-labeledcyanoindol-cyclohexylamine derivatives as radioligand for the serotonin trasporter. J. Labl. Comp. Radiopharm. 2009, 52 :S377-377.
38. Y. Krausz, N. Freedman, R. Rubinstein, E. Mishani, E. Lavie, A.Y. Bross, D. Vaknin, K. Ben-Meir, R. Michael, M. Orevi, S. Tshori, A. Salmon, B. Glaser, R. Chisin, D.j. Gross. Ga-68-DOTA-NOC PET/CT in nueuroendocrine Tumors – Comparison with In-111-DTPA-Octreotide. World Molecular Imaging Congress, Montreal, Canada, 2009.
39. Allen, A. M. Shirvan, A. Mishani, E. Steinmetz, A. Reshef, A. Ziv, I. Fenig, E. Early Prediction of Radiation Response of Brain Metastases with [F-18]-ML-10: A Novel Molecular PET Imaging Agent for Apoptosis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 75, 3, S44-S44. 2009.
40. Martine Klein, Ofer Gofrit, Eyal Mishani, Roland Chisin and Marina Orevi. Intraindividual comparison of 11C-choline and 11C-acetate PET/CT in bladder TCC. The 56 annual Conference of the Society of Nuclear Medicine, Toronto, Canada. 2009.)
41. Krausz, Yodphat; Rubinstein, Rina; Mishani, Eyal; Orevi, Marina; Tshori, Sagi; Salmon, Asher Y; Glaser, Benjamin; Chisin, Roland; Gross, David J; Freedman, Nanette M. Ga68-DOTANOC uptake in the pancreas: pathological significance? The 57 annual Conference of the Society of Nuclear Medicine, Salt Lake City, Utah, USA. 2010.